Drug ID:Drug23
Drug Name:Indomethacin
CID:3715
DrugBank ID:DB00328
Modality:Small Molecule
Groups:approved|investigational
US Approved:YES
Other Approved:YES
Identifier: NCT05999708
Molecular Formula:C19H16ClNO4
Molecular Weight:357.8 g/mol
Isomeric SMILES:CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
Synonyms:indomethacin; 53-86-1; indometacin; Indomethacine; Indometacine; Reumacide; Indomethazine; Artrinovo; Confortid; Idomethine
Phase 0: 6
Phase 1: 22
Phase 2: 34
Phase 3: 40
Phase 4: 33
Description:Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt209 3715 Indomethacin 2215 FCGR3B Homo sapiens (human) None
dt210 3715 Indomethacin 133 ADM Homo sapiens (human) None
dt211 3715 Indomethacin 7442 TRPV1 Homo sapiens (human) None
dt212 3715 Indomethacin 7298 TYMS Homo sapiens (human) None
dt213 3715 Indomethacin 4609 MYC Homo sapiens (human) None
dt214 3715 Indomethacin 10468 FST Homo sapiens (human) None
dt215 3715 Indomethacin 1636 ACE Homo sapiens (human) None
dt216 3715 Indomethacin 5743 PTGS2 Homo sapiens (human) None
dt217 3715 Indomethacin 9536 PTGES Homo sapiens (human) None
dt218 3715 Indomethacin 1576 CYP3A4 Homo sapiens (human) None

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05999708 A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants PHASE1 WITHDRAWN GlaxoSmithKline Colitis, Ulcerative DRUG: GSK4381406|DRUG: Placebo|DRUG: Indomethacin Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Protective Effect of Hydroalcoholic Root Extract of Rubia cordifolia in Indomet…

PMID: 22303076
Year: 2011
Relationship Type: Treatment Score: 6.1

This study was undertaken to investigate the possible effect of hydroalcoholic root extract of Rubia cordifolia against indomethacin-induced enteroco…

View Details
TNF-alpha modulates iNOS expression in an experimental rat model of indomethaci…

PMID: 19802525
Year: 2010
Relationship Type: Treatment Score: 6.1

Multiple mucosal immune factors, such as TNF-alpha and IL-1beta, are thought to be key mediators involved in inflammatory bowel disease. We evaluated…

View Details
Showing 21-22 of 22 articles